Association analysis of SNPs present in plasma with adverse events and population pharmacokinetics in Chinese sunitinib treated patients with renal cell carcinoma

BACKGROUND: Sunitinib is a tyrosine kinase inhibitor with effective therapeutic outcomes in patients with renal-cell carcinoma. The study were to analyze the association of single-nucleotide polymorphisms present in cell-free DNA and pharmacokinetics with sunitinib treatment-emergent adverse events...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuanyuan, Mai, Haixing, Guo, Gang, Bi, Guofang, Hao, Guangtao, Li, Yuanyuan, Wang, Xiaofang, Cheng, Longmei, Wang, Jing, Dong, Ruihua, Liu, Zeyuan, Chen, Lijun, Qu, Hengyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865657/
https://www.ncbi.nlm.nih.gov/pubmed/29581831
http://dx.doi.org/10.18632/oncotarget.23881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865657/
https://www.ncbi.nlm.nih.gov/pubmed/29581831
http://dx.doi.org/10.18632/oncotarget.23881

Ejemplares similares